To test this hypothesis, we used two drugs in clinical practice or clinical development: Dasatinib, a BCR/ABL and SRC family tyrosine kinases inhibitor used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) (Lindauer and Hochhaus, 2014), and Erdafitinib, a potent pan-FGFR inhibitor (Perera et al., 2017) in clinical testing in advanced solid tumors, including breast, prostate, colon, bladder, esophageal and non-small-cell lung cancers (www.clinicaltrials.gov). This evidence concerns the gene SRC and acute lymphoblastic leukemia.